0001415889-22-000401.txt : 20220105
0001415889-22-000401.hdr.sgml : 20220105
20220105200014
ACCESSION NUMBER: 0001415889-22-000401
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Trachtenberg Eric
CENTRAL INDEX KEY: 0001646300
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 22513257
MAIL ADDRESS:
STREET 1: 1414 RALEIGH ROAD
STREET 2: SUITE 400
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
4
1
form4-01052022_080105.xml
X0306
4
2022-01-03
0001479419
Kala Pharmaceuticals, Inc.
KALA
0001646300
Trachtenberg Eric
C/O KALA PHARMACEUTICALS, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
false
true
false
false
SEE REMARKS
Common Stock
2022-01-04
4
S
0
2850
1.30
D
113816
D
Stock Option (right to buy)
1.37
2022-01-03
4
A
0
153000
0
A
2032-01-03
Common Stock
153000
153000
D
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 53,611 unvested RSUs.
This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.
General Counsel, Chief Compliance Officer and Secretary
/s/ Eric Trachtenberg
2022-01-05